

=&gt; d bib abs hitstr 20

L15 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1995:896112 CAPLUS

DN 123:314540

TI Preparation of heterocyclylpeptides and related compounds as inhibitors of

thrombocyte aggregation, cancer cell metastasis, and binding of osteoclasts to bone surfaces.

IN Zoller, Gerhard; Klingler, Otmar; Jablonka, Bernd; Just, Melitta;

Breipohl, Gerhard; Knolle, Jochen; Koenig, Wolfgang; Stilz, Hans Ulrich

PA Cassella AG, Germany

SO Ger. Offen., 19 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4338944	A1	19950518	DE 1993-4338944	19931115
	DE 4427979	A1	19960215	DE 1994-4427979	19940808
	WO 9514008	A1	19950526	WO 1994-EP3491	19941024
	W: AU, CA, CN, CZ, FI, HU, JP, KR, PL, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2169643	AA	19950526	CA 1994-2169643	19941024
	AU 9479397	A1	19950606	AU 1994-79397	19941024
	AU 693811	B2	19980709		
	EP 729460	A1	19960904	EP 1994-930215	19941024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	CN 1134696	A	19961030	CN 1994-194043	19941024
	HU 74736	A2	19970228	HU 1996-1300	19941024
	JP 09505062	T2	19970520	JP 1994-514176	19941024
	ZA 9409017	A	19950515	ZA 1994-9017	19941114
	FI 9602043	A	19960514	FI 1996-2043	19960514
	US 5981492	A	19991109	US 1996-640895	19960719
PRAI	DE 1993-4338944		19931115		
	DE 1994-4427979		19940808		
	WO 1994-EP3491		19941024		
OS	MARPAT 123:314540				
GI					



AB Title compds. [I; W = R1ACR13, R1ACH:C; Y = CO, CS, CH2; Z = NR, O, S, CH2; A = (cyclo)alkylene, phenylene, phenylenealkyl, phenylenealkenyl, (substituted) divalent N-contg. heterocycle; B = alkylene, alkenylene, phenylene, phenylenealkyl; D = CR2R3, CHCR3; E = tetrazolyl, (R8O)2PO, HO3S, R9NHSO2, R10CO; R = H, alkyl, cycloalkyl, (substituted) aryl, aralkyl; R1 = XNHC(:NH)(CH2)p, X1NH(CH2)p; p = 0-3; X = H, alkyl, alkylcarbonyl, alkoxy carbonyl, cyano, OH, amino, (substituted) arylcarbonyl, etc.; X1 = X, R'NHC(:NR''); R', R'' = X; R2 = H, alkyl, (substituted) aryl, aralkyl, cycloalkyl; R3 = R2, alkenyl, alkynyl, alkenylcarbonyl, alkynylcarbonyl, pyridyl, etc.; R8 = H, alkyl, (substituted) aryl, aralkyl; R9 = H, aminocarbonyl, alkylaminocarbonyl, alkyl, (substituted) aryl, cycloalkyl; R10 = OH, alkoxy, (substituted) arylalkoxy, aryloxy, amino; R13 = H, alkyl, (substituted) aralkyl, cycloalkyl; b, c, d, f = 0, 1; e, g, h = 0-6], were prepd. as inhibitors of cell-cell adhesion dependent on the interaction of Arg-Gly-Asp contg. proteins and other adhesive proteins (no data). Thus, [[(S,R)-4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]acetylasparylphenylglycine was prepd. by soln. phase methods.

IT 169807-87-8P 169807-88-9P 169807-89-0P  
169807-90-3P 169807-91-4P 169807-92-5P  
169807-93-6P 169807-94-7P 169807-95-8P  
169807-96-9P 169807-97-0P 169807-98-1P  
169807-99-2P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclipeptides and related compds. as inhibitors of thrombocyte aggregation, cancer cell metastasis, and binding of osteoclasts to bone surfaces)

RN 169807-87-8 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169807-88-9 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488




RN 169807-89-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-[imino(methoxycarbonyl)amino)methyl]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-90-3 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-91-4 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169807-92-5 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169807-93-6 CAPLUS

CN Glycine, N-[[4-[4-(aminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-94-7 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-95-8 CAPLUS

CN Glycine, N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-96-9 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169807-97-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p


henyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169807-98-1 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 169807-99-2 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 169808-02-0P 169808-03-1P 169808-05-3P  
169808-10-0P 169808-22-4P 169808-23-5P  
169808-24-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heterocyclipeptides and related compds. as inhibitors of  
thrombocyte aggregation, cancer cell metastasis, and binding of  
osteoclasts to bone surfaces)

RN 169808-02-0 CAPLUS

CN Glycine, N-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, bis(1,1-dimethylethyl) ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 169808-03-1 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169808-05-3 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488




● 2 HCl

RN 169808-10-0 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, bis(1,1-dimethylethyl) ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169808-22-4 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-

4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169808-23-5 CAPLUS

CN L-Alanine, 3-[[[4-[[4-(aminoiminomethyl)phenyl)methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169808-24-6 CAPLUS


CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p

henyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— Ph

=&gt; d bib abs hitstr 22

L15 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1994:580230 CAPLUS

DN 121:180230

TI Preparation of phenylimidazolidine derivatives as cell adhesion inhibitors

IN Zoller, Gerhard; Jablonka, Bernd; Just, Melitta; Klingler, Otmar; Breipohl, Gerhard; Knolle, Jochen; Koenig, Wolfgang

PA Cassella AG, Germany

SO Eur. Pat. Appl., 22 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 580008	A2	19940126	EP 1993-110754	19930706
	EP 580008	A3	19950315		
	EP 580008	B1	19980708		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	DE 4224414	A1	19940127	DE 1992-4224414	19920724
	JP 07025855	A2	19950127	JP 1993-163042	19930701
	AT 168116	E	19980715	AT 1993-110754	19930706
	ES 2119837	T3	19981016	ES 1993-110754	19930706
	US 5424293	A	19950613	US 1993-95905	19930722
	CA 2101179	AA	19940125	CA 1993-2101179	19930723
	AU 9342119	A1	19940127	AU 1993-42119	19930723
	AU 664630	B2	19951123		
	ZA 9305341	A	19940214	ZA 1993-5341	19930723
	HU 65141	A2	19940428	HU 1993-2138	19930723
	IL 106462	A1	19970218	IL 1993-106462	19930723
PRAI	DE 1992-4224414		19920724		
OS	MARPAT 121:180230				
GI					



AB Title. compds. [I; R, R2 = H, alkyl; R1 = C6H4(CH2)nNHX, C6H4(CH2)pC(:NH)NHX1; R3 = H, (substituted)Ph; R4 = H, CO2H, alkoxy carbonyl, CONH2, etc.; W = OH, alkoxy, NH2, etc.; X = (substituted)C(:NH)NH2; X,X1 = H, alkyl, alkanoyl, alkoxy carbonyl, etc.;

Y = (CH2)mCO, C6H4CO; Z = O, S; m = 1-4; n,p,r = 0-3] were prepd. Thus,

Searched by John Dantzman 308-4488


4-(H<sub>2</sub>N)C<sub>6</sub>H<sub>4</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>Me.HCl was converted in 5 steps to [5-(4-guanidinophenyl)-2,4-dioxoimidazolidin-3-yl]acetyl-L-aspartyl-L-phenylglycine which had IC<sub>50</sub> of 0.2 and 0.07.μM against ADP- and thrombin-induced thrombocyte aggregation, resp.

IT 157550-19-1P 157550-25-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction of, in prepn. of cell adhesion inhibitor)

RN 157550-19-1 CAPLUS

CN Glycine, N-[N-[[4-[4-[[imino(nitroamino)methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 157550-25-9 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[[(1,1-dimethylethoxy) carbonyl]amino]methyl]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 157549-93-4P 157549-94-5P 157549-95-6P

157549-96-7P 157549-97-8P 157549-98-9P

157549-99-0P 157550-00-0P 157550-01-1P

157550-03-3P 157550-04-4P 157550-05-5P

157550-06-6P 157550-07-7P 157550-08-8P

157550-09-9P 157550-10-2P 157550-11-3P

157550-12-4P 157550-13-5P 157550-14-6P

157550-15-7P

RL: SPN (Synthetic preparation); PREP (Preparation)


Searched by John Dantzman 308-4488

(prepn. of, as cell adhesion inhibitor)

RN 157549-93-4 CAPLUS

CN Glycine, N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157549-94-5 CAPLUS

CN Glycine, N-[[4-[3-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157549-95-6 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminomethyl)phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157549-96-7 CAPLUS

CN Glycine, N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-D-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488

Absolute stereochemistry.




RN 157549-97-8 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p


henyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,  
bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 157549-98-9 CAPLUS

CN Glycine, N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-  
imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,  
bis(1-methylethyl)

ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


Searched by John Dantzman

308-4488



RN 157549-99-0 CAPLUS

CN Glycine, N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 157550-00-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(methoxycarbonyl)amino]methyl](methoxycarbonyl

1)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, diethyl ester (9CI) (CA INDEX NAME)




RN 157550-01-1 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[[ (phenylmethoxy) carbonyl]amino]methyl]amino]p

henyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(2-methylpropyl) ester (9CI) (CA INDEX NAME)



RN 157550-03-3 CAPLUS


CN Glycine, N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(2-methylpropyl) ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 157550-02-2

CMF C32 H41 N7 O8


CDES 5:L,L



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 157550-04-4 CAPLUS

CN Glycine,


N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p

henyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 157550-05-5 CAPLUS

CN Glycine, N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 157550-06-6 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (9CI) (CA INDEX NAME)




RN 157550-07-7 CAPLUS

CN Glycine,


N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,

1-methyl ester (9CI) (CA INDEX NAME)




RN 157550-08-8 CAPLUS

CN Glycine, N-[N-[[4-[4-[[imino(methoxycarbonyl)amino]methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI)  
(CA INDEX NAME)




RN 157550-09-9 CAPLUS

CN Glycine, N-[N-[[4-[4-[[imino(methoxycarbonyl)amino]methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 157550-10-2 CAPLUS

CN Glycine, N-[N-[[4-[4-[[imino(methoxycarbonyl)amino]methyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, 1-hexadecyl 4-(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 157550-11-3 CAPLUS

CN Glycine,

N-[N-[[4-[4-[(acetylamino)iminomethyl]amino]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,

bis(1-methylethyl)

ester (9CI) (CA INDEX NAME)




RN 157550-12-4 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminomethyl)phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,

bis(1-methylethyl)

ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 157550-13-5 CAPLUS

CN Glycine, N-[N-[[4-[4-[(acetylamino)methyl]phenyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,

bis(1-methylethyl)

ester (9CI) (CA INDEX NAME)



PAGE 1-B

—CH<sub>2</sub>—CH<sub>2</sub>—OH

IT 157549-97-8


RL: RCT (Reactant)

(reaction of, in prepn. of cell adhesion inhibitor)

RN 157549-97-8 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p

henyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-,  
bis(1-methylethyl) ester (9CI) (CA INDEX NAME)


=&gt; d bib abs hitstr 14

L15 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1997:515846 CAPLUS  
 DN 127:131010  
 TI Agents for promoting bone formation  
 IN Kitamura, Kazuyuki; Komiyama, Osamu; Inazu, Mizuho; Baron, Roland; Gadek, Thomas; Knolle, Jochen; Stilz, Han-Ulrich; Wehner, Volkmar; Mcdowell, Robert S.  
 PA Roussel-UCLAF, Fr.; Kitamura, Kazuyuki; Komiyama, Osamu; Inazu, Mizuho; Baron, Roland; Gadek, Thomas; Knolle, Jochen; Stilz, Han-Ulrich; Wehner, Volkmar; Mcdowell, Robert S.  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721726	A1	19970619	WO 1996-EP5380	19961206
	W: CA, IL, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	JP 09157181	A2	19970617	JP 1995-345057	19951208
	CA 2236335	AA	19970619	CA 1996-2236335	19961206
	EP 865446	A1	19980923	EP 1996-942315	19961206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	JP 1995-345057		19951208		
	WO 1996-EP5380		19961206		
OS	MARPAT 127:131010				
AB	The object is to provide a promoting agent for bone formation, a therapeutic method for bone formation and a process for prepg. a promoting agent for bone formation. A promoting agent for bone formation which comprises at least one of kistrin, echstatin, a peptide or polypeptide contg. the amino acid sequence ArgGlyAsp in the mol. such as a peptide represented by Gly-Arg-Gly-Asp-Ser, and other compds. as well as a biol. acceptable salt thereof.				
IT	<b>192710-67-1</b>				
	RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (agents for promoting bone formation)				
RN	192710-67-1 CAPLUS				
CN	L-Alanine, 3-[[[(4S)-4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA				
INDEX	NAME)				

Absolute stereochemistry.





=> d bib abs hitstr 15

L15 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1997:16542 CAPLUS

DN 126:118187

TI From peptides to heterocyclic peptide mimetics - design and synthesis of an orally active fibrinogen receptor antagonist for the prevention of thrombosis

AU Stilz, H.U.; Beck, G.; Jablonka, B.; Just, M.

CS Central Pharma Research, Frankfurt am Main, D-65926, Germany

SO Bull. Soc. Chim. Belg. (1996), 105(10-11), 711-719



CODEN: BSCBAG; ISSN: 0037-9646

PB Societe Chimique Belges

DT Journal

LA English

GI



AB The binding of fibrinogen to the platelet fibrinogen receptor (GP IIb/IIIa

receptor) depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif. Structural modifications of the RGDS tetrapeptide structure has led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist

I

(S-1197). I inhibited dose-dependently and reversibly human platelet aggregation. In conscious dogs, II (S-5740) showed a high plasma availability of the active moiety of 42.+-8% (n = 4) and a plasma half life of 9.9 h after oral administration as measured by bioassay. II may potentially be used for chronic treatment and prophylaxis of thrombotic diseases in humans. A pilot plant synthesis of II was developed.

IT **177563-39-2P 177563-41-6P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of heterocyclic peptide mimetics as orally active fibrinogen

Searched by John Dantzman 308-4488

receptor antagonists for prevention of thrombosis)  
RN 177563-39-2 CAPLUS  
CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride,  
[S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 177563-41-6 CAPLUS  
CN Benzenepropanoic acid, .beta.-[[[(4S)-4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester,  
(.beta.S)-,  
monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 177563-40-5  
CMF C24 H27 N5 O5

Absolute stereochemistry. Rotation (-).




Searched by John Dantzman

308-4488

CM 2

CRN 64-19-7

CMF C2 H4 O2



IT 186183-13-1P 186183-15-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of heterocyclic peptide mimetics as orally active fibrinogen  
receptor antagonists for prevention of thrombosis)

RN 186183-13-1 CAPLUS

CN Benzenepropanoic acid,

.beta.-[[[4-[4-[(hydroxyamino)iminomethyl]phenyl]-4-  
methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester,  
[S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186183-15-3 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-(4-cyanophenyl)-4-methyl-2,5-dioxo-1-  
imidazolidinyl]acetyl]amino]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry. Rotation (-).



=> d bib abs hitstr 16

L15 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1997:5805 CAPLUS

DN 126:31350

TI Preparation of dioxoimidazolidinylacetates and analogs as pharmaceutical intermediates

IN Zoller, Gerhard; Klingler, Omar; Knolle, Jochen; Stilz, Hans Ulrich; Wehner, Volkmar

PA Cassella Ag, Germany

SO Ger. Offen., 25 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19515177	A1	19961031	DE 1995-19515177	19950428
	WO 9633976	A1	19961031	WO 1996-EP1572	19960415
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2219359	AA	19961031	CA 1996-2219359	19960415
	EP 823898	A1	19980218	EP 1996-914914	19960415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	JP 11504024	T2	19990406	JP 1996-532132	19960415
	US 5939556	A	19990817	US 1997-952322	19971027
PRAI	DE 1995-19515177		19950428		
	WO 1996-EP1572		19960415		
OS	MARPAT 126:31350				
GI					



AB Title compds. [I; R = cyano, alkoxyiminomethyl, C(:NH)NHR6, CH2NHR6, etc.;

R1 = (cyclo)alkyl, (un)substituted aralkyl; R2 = H, (cyclo)alkyl, (un)substituted aryl(alkyl); R3 = H, CH2CO2R4; R4 = H, alkyl, aryl(alkyl),

etc.] were prepd. Thus, 4-BrC6H4COMe was cyclocondensed with KCN/(NH4)2CO3 to give I (R = Br, R1 = Me, R2 = R3 = H) which was converted

in 4 steps to (S)-4-BrC6H4CMe(NH2)CO2Et. The latter was amidated by OCNCH2CO2Et and the product cyclized to give, after cyanation, (S)-I (R = cyano, R1 = Me, R2 = R3 = H).

Searched by John Dantzman 308-4488

IT 184427-31-4P 184427-32-5P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of dioxoimidazolidinylacetates and analogs as pharmaceutical intermediates)

RN 184427-31-4 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester, monohydrochloride,  
[S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 184427-32-5 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-(4-cyanophenyl)-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester, monohydrochloride,  
[S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

Searched by John Dantzman

308-4488

QAZI

08/971960

Page 9

Searched by John Dantzman


308-4488



=> d bib abs hitstr 17

L15 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2000 ACS  
AN 1996:280841 CAPLUS  
DN 125:25635  
TI Discovery of an Orally Active Non-Peptide Fibrinogen Receptor Antagonist  
AU Stilz, Hans Ulrich; Jablonka, Bernd; Just, Melitta; Knolle, Jochen;  
Paulus, Erich Friedrich; Zoller, Gerhard  
CS Hoechst AG, Frankfurt/Main, D-65926, Germany  
SO J. Med. Chem. (1996), 39(11), 2118-2122  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
AB The discovery of the potent GPIIb/IIIa antagonist S 1197 and of the resp.  
ester prodrug S 5740 is reported. S 1197, a non-peptide RGD mimetic, was  
derived from the initial Arg-Gly-Asp-Ser tetrapeptide lead by the  
discovery of the hydantoin moiety to conformationally constrain the  
linear  
peptide chain, by the observation that the exchange of the Asp-Ser moiety  
at the carboxyl-terminus with an Asp-Phe moiety considerably improves the  
potency of compds., and by the finding that the introduction of a .beta.  
amino acid at the carboxyl-terminus in place of the Asp-Phe moiety  
improves the oral activity. Compd. S 1197 inhibited dose-dependently and  
reversibly human and dog platelet aggregation. 125I-fibrinogen binding  
to  
ADP-activated human gel filtered platelets and isolated GPIIb/IIIa with  
Ki-values of 9 nM and 0.17 nM, resp. The Et ester prodrug S 5740 showed  
in conscious dogs a high plasma availability of the active moiety of 42%  
and a plasma half life of 9.9 h after oral administration as measured by  
bioassay. Compd. S 5740 may potentially be used for chronic treatment  
and  
prophylaxis of thrombotic diseases.  
IT 170717-42-7 170717-43-8 177563-42-7  
177563-43-8  
RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)  
(orally active non-peptide fibrinogen receptor antagonist and its  
prodrug)  
RN 170717-42-7 CAPLUS  
CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-  
imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (R)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 170717-43-8 CAPLUS

CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177563-42-7 CAPLUS

CN L-Serine,  
N-[N-[[4-[[3-[(aminoiminomethyl)amino]propyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177563-43-8 CAPLUS

CN Glycine,  
N-[N-[[4-[[3-[(aminoiminomethyl)amino]propyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488

Absolute stereochemistry.



IT 177563-39-2P 177563-41-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of S 1197, an orally active non-peptide fibrinogen receptor antagonist, and its prodrug S 5740)


RN 177563-39-2 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride,

[S-(R\*,R\*)]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 177563-41-6 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[(4S)-4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester,

(.beta.S)-,

monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 177563-40-5

CMF C24 H27 N5 O5

Searched by John Dantzman


308-4488

Absolute stereochemistry. Rotation (-).



CM 2

CRN 64-19-7  
CMF C2 H4 O2



IT 170565-27-2 170565-36-3 170565-37-4  
170565-44-3 170565-45-4 170565-46-5  
170565-47-6 170565-51-2 177563-44-9


RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)

(structure activity in discovery of an orally active non-peptide  
fibrinogen receptor antagonist)


RN 170565-27-2 CAPLUS

CN 1-Naphthalenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-  
methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 170565-36-3 CAPLUS  
CN 3-Pyridinepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-37-4 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-44-3 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[(4R)-4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-45-4 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-46-5 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-47-6 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170565-51-2 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 177563-44-9 CAPLUS

Searched by John Dantzman

308-4488



CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 18

L15 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1995:947889 CAPLUS

DN 124:146807

TI Synthesis of

[5-(4-formamidino-benzyl)-2,4-dioxo-imidazolidin-3-yl]-acetyl-L-aspartyl-L-valine

AU Chen, Anli; Chen, Weixin

CS Technische Fachhochschule Darmstadt, Germany

SO Huadong Ligong Daxue Xuebao (1995), 21(4), 481-7

CODEN: HLIKEV

DT Journal

LA Chinese

AB According to the mechanism of the inhibiting action of peptide Arg-Gly-Asp

on platelet aggregation, the title peptide (I) was designed and synthesized. I showed potent platelet aggregation activity.

IT 150376-03-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis of

(formamidinobenzyl)dioxoimidazolidinylacetylaspartylvaline)

RN 150376-03-7 CAPLUS

CN L-Valine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 150376-14-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (synthesis of

(formamidinobenzyl)dioxoimidazolidinylacetylaspartylvaline)

RN 150376-14-0 CAPLUS

CN L-Valine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 19

L15 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1995:931237 CAPLUS

DN 123:340969

TI Preparation of substituted 5-member-ring heterocyclic-compound blood platelet aggregation inhibitors and anticancer agents

IN Zoller, Gerhard; Klingler, Otmar; Jablonka, Bernd; Just, Melitta;

Breipohl, Gerhard; Knolle, Jochen; Koenig, Wolfgang; Stilz, Hans-Ulrich

PA Cassella Aktiengesellschaft, Germany

SO PCT Int. Appl., 103 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9514008	A1	19950526	WO 1994-EP3491	19941024
	W: AU, CA, CN, CZ, FI, HU, JP, KR, PL, RU, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 4338944	A1	19950518	DE 1993-4338944	19931115
	DE 4427979	A1	19960215	DE 1994-4427979	19940808
	AU 9479397	A1	19950606	AU 1994-79397	19941024
	AU 693811	B2	19980709		
	EP 729460	A1	19960904	EP 1994-930215	19941024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	JP 09505062	T2	19970520	JP 1994-514176	19941024
	FI 9602043	A	19960514	FI 1996-2043	19960514
	US 5981492	A	19991109	US 1996-640895	19960719
PRAI	DE 1993-4338944		19931115		
	DE 1994-4427979		19940808		
	WO 1994-EP3491		19941024		
OS	MARPAT 123:340969				
GI					



AB The title compds. (I; W,Y,Z,B,D,E, and R, as well as b,c,d,e,f,g, and h are defined in the patent application claims) [e.g., [(R,S)-4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxoimidazolidin-1-yl]acetyl-L-aspartyl-L-phenylglycine; II], useful as inhibitors of blood platelet aggregation (e.g., II demonstrated a IC50 of 0.05 .mu.M for thrombin-stimulated platelet aggregation), inhibitors of metastasis of

Searched by John Dantzman 308-4488

cancerous cells, and inhibitors of the attachment of osteoclasts to bone surfaces, are prepd.

IT 169807-87-8P 169807-88-9P 169807-89-0P  
169807-90-3P 169807-91-4P 169807-92-5P  
169807-93-6P 169807-94-7P 169807-95-8P  
169807-96-9P 169807-97-0P 169807-98-1P  
169807-99-2P 170565-05-6P 170565-06-7P  
170565-07-8P 170565-08-9P 170565-09-0P  
170565-11-4P 170565-12-5P 170565-13-6P  
170565-14-7P 170565-15-8P 170565-16-9P  
170565-17-0P 170565-18-1P 170565-19-2P  
170565-20-5P 170565-21-6P 170565-22-7P  
170565-23-8P 170565-24-9P 170565-25-0P  
170565-26-1P 170565-27-2P 170565-28-3P  
170565-29-4P 170565-30-7P 170565-31-8P  
170565-32-9P 170565-33-0P 170565-34-1P  
170565-35-2P 170565-36-3P 170565-37-4P  
170565-38-5P 170565-39-6P 170565-40-9P  
170565-41-0P 170565-42-1P 170565-43-2P  
170565-44-3P 170565-45-4P 170565-46-5P  
170565-47-6P 170565-48-7P 170565-49-8P  
170565-50-1P 170565-51-2P 170565-52-3P  
170565-53-4P 170565-54-5P 170717-42-7P  
170717-43-8P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted 5-member-ring heterocyclic-compd. blood platelet aggregation inhibitors and anticancer agents)

RN 169807-87-8 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-88-9 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169807-89-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-90-3 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-91-4 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169807-92-5 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169807-93-6 CAPLUS

CN Glycine, N-[[4-[[4-(aminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169807-94-7 CAPLUS

CN L-Alanine, 3-[[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 169807-95-8 CAPLUS

CN Glycine, N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169807-96-9 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 169807-97-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p


henyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169807-98-1 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 169807-99-2 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 170565-05-6 CAPLUS

CN Glycine,

N-[N-[[4-[4-[(aminoiminomethyl)amino]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 170565-06-7 CAPLUS

CN L-Phenylalanine,

N-[N-[[4-[4-[[imino[(methoxycarbonyl)amino]methyl]amino]phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-07-8 CAPLUS

CN 1-Imidazolidineacetic acid,


4-[4-[(aminoiminomethyl)amino]phenyl]-4-methyl-2,5-dioxo-, 2-(carboxymethyl)-2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 170565-08-9 CAPLUS

CN 1-Imidazolidineacetic acid,


4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]phenyl]-4-methyl-2,5-dioxo-, 2-(2-methoxy-2-oxoethyl)-2-[(phenylmethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 170565-09-0 CAPLUS

CN 1-Imidazolidineacetic acid,

4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]phenyl]-4-methyl-2,5-dioxo-, 1-(carboxymethyl)-2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 170565-11-4 CAPLUS


CN 1-Imidazolidineacetic acid,

4-[[4-(aminoiminomethyl)phenyl]methylene]-2,5-

Searched by John Dantzman

308-4488


dioxo-, 1-(carboxymethyl)-2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI)  
(CA INDEX NAME)



RN 170565-12-5 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, 2-methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-13-6 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-3-ethyl-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-14-7 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-15-8 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-cyclopropyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170565-16-9 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-ethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

(NAME)

Absolute stereochemistry.




RN 170565-17-0 CAPLUS

CN Glycine,

N-[N-[[4-[4-(aminoiminomethyl)phenyl]-2,5-dioxo-4-(phenylmethyl)-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170565-18-1 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-(1,1-dimethylethyl)-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 170565-19-2 CAPLUS

CN Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-(1-oxohexyl)- (9CI) (CA INDEX NAME)




RN 170565-20-5 CAPLUS

CN Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-(1-oxohexyl)- (9CI) (CA INDEX NAME)




RN 170565-21-6 CAPLUS

CN Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-(butylsulfonyl)- (9CI) (CA INDEX NAME)




RN 170565-22-7 CAPLUS

CN Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-(butylsulfonyl)- (9CI) (CA INDEX NAME)




RN 170565-23-8 CAPLUS

CN Alanine, N-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-3-[[[(phenylamino)carbonyl]amino]sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 170565-24-9 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)



RN 170565-25-0 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-hydroxy-3-methoxy- (9CI) (CA INDEX NAME)



RN 170565-26-1 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-ethoxy- (9CI) (CA INDEX NAME)


Searched by John Dantzman 308-4488



RN 170565-27-2 CAPLUS

CN 1-Naphthalenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



Searched by John Dantzman


308-4488

PAGE 2-A




RN 170565-28-3 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3-nitro- (9CI) (CA INDEX NAME)




RN 170565-29-4 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-carboxy- (9CI) (CA INDEX NAME)



RN 170565-30-7 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 170565-31-8 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3-carboxy- (9CI) (CA INDEX NAME)


Searched by John Dantzman

308-4488




RN 170565-32-9 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 170565-33-0 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 170565-34-1 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 170565-35-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)

308-4488




4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-36-3 CAPLUS


CN 3-Pyridinepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-37-4 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488




RN 170565-38-5 CAPLUS

CN Cyclohexanepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-39-6 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 170565-40-9 CAPLUS

Searched by John Dantzman

308-4488


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 170565-41-0 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-3-ethyl-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-42-1 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-3-ethyl-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170565-43-2 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 170565-44-3 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4R)-4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-45-4 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-46-5 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170565-47-6 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170565-48-7 CAPLUS


CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 170565-49-8 CAPLUS

CN 3-Pyridinepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]methylamino]- (9CI) (CA INDEX NAME)




RN 170565-50-1 CAPLUS

CN Benzenepropanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]methylamino]- (9CI) (CA INDEX NAME)




RN 170565-51-2 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, .beta.-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 170565-52-3 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo-4-(tricyclo[3.3.1.3^7]dec-1-ylamino)- (9CI) (CA INDEX NAME)



RN 170565-53-4 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo-4-(tricyclo[3.3.1.3^7]dec-2-ylamino)- (9CI) (CA INDEX NAME)





RN 170565-54-5 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo-4-[(tricyclo[3.3.1.3<sup>0</sup>,7]dec-1-ylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 170717-42-7 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170717-43-8 CAPLUS

CN Glycine, N-[N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 170564-93-9 170564-96-2


RL: RCT (Reactant)

(prepn. of substituted 5-member-ring heterocyclic-compd. blood platelet

aggregation inhibitors and anticancer agents from)

RN 170564-93-9 CAPLUS


CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo-4-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-ylamino)-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170564-96-2 CAPLUS

CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo-4-[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)amino]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 169808-02-0P 169808-03-1P 169808-05-3P

169808-10-0P 169808-22-4P 169808-23-5P

169808-24-6P 170565-02-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of substituted 5-member-ring heterocyclic-compd. blood platelet aggregation inhibitors and anticancer agents from)

RN 169808-02-0 CAPLUS

CN Glycine, N-[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, bis(1,1-dimethylethyl) ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169808-03-1 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 169808-05-3 CAPLUS

CN L-Alanine, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 169808-10-0 CAPLUS

CN Glycine, N-[[[4-[4-(aminoiminomethyl)phenyl]-3,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-2-phenyl-, bis(1,1-dimethylethyl) ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

Absolute stereochemistry.



● HCl


RN 169808-22-4 CAPLUS

CN Glycine,

N-[N-[[4-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-

4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-  
, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169808-23-5 CAPLUS

CN L-Alanine, 3-[[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-  
imidazolidinyl]acetyl]amino]-N-[(phenylmethoxy)carbonyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169808-24-6 CAPLUS


CN Glycine,

N-[N-[[4-[4-[[imino[(phenylmethoxy)carbonyl]amino]methyl]amino]p

henyl]-4-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Ph

RN 170565-02-3 CAPLUS

CN Butanoic acid, 3-[[[4-[4-(aminoiminomethyl)phenyl]-4-methyl-2,5-dioxo-1-

imidazolidinyl]acetyl]amino]-4-oxo-4-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylamino)-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

=> d bib abs hitstr 21

L15 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1994:580236 CAPLUS  
 DN 121:180236  
 TI Preparation of imidazolidin derivatives as blood platelet aggregation inhibitors  
 IN Zoller, Gerhard; Jablonka, Bernd; Just, Melitta; Klingler, Otmar; Breipohl, Gerhard; Knolle, Jochen; Koenig, Wolfgang  
 PA Cassella Aktiengesellschaft, Germany  
 SO Eur. Pat. Appl., 21 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 584694	A1	19940302	EP 1993-113143	19930817
	EP 584694	B1	19980121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	DE 4228717	A1	19940303	DE 1992-4228717	19920828
	JP 07053590	A2	19950228	JP 1993-163037	19930701
	AT 162531	E	19980215	AT 1993-113143	19930817
	ES 2112361	T3	19980401	ES 1993-113143	19930817
	CA 2105014	AA	19940301	CA 1993-2105014	19930827
	AU 9344914	A1	19940303	AU 1993-44914	19930827
	AU 663213	B2	19950928		
	ZA 9306306	A	19940322	ZA 1993-6306	19930827
	HU 65552	A2	19940628	HU 1993-2439	19930827
	US 5554594	A	19960910	US 1995-456066	19950531
PRAI	DE 1992-4228717		19920828		
	US 1993-98123		19930727		
OS	CASREACT 121:180236; MARPAT 121:180236				
GI					




AB Title compds. I [R = H, C1-6 alkyl; R1 = (CH2)n-NH-X, etc.; n = 1-6  
 Searched by John Dantzman 308-4488




integer; X = H, C1-6 alkyl, C1-6 alkoxy, etc.; Y = Q; r = 0-3, W = OH, C1-28 alkyl, arylalkoxy, aryloxy, amino, mono- or dialkylamino; Z = S; R2 = H, C1-6 alkyl; R3 = O, phenyl; R4 = CO2-R5, CO-NMe-R5, CO-NH-R5; R5 = C1-28 alkyl, etc.], useful as blood platelet aggregation inhibitors (no data), are prepd. via condensation of the benzoic acid deriv. II with the amine III. E.g., condensation of N,N.omega.-bis(benzyloxycarbonyl)ornithine benzyl ester hydrochloride with Et m-isocyanatobenzoate in DMF contg. N-ethylmorpholine gave N-(S)-[(benzyloxycarbonylamino)[3-(benzyloxycarbonylamino)propyl]methyl]-N'-(3-ethoxycarbonylphenyl)urea, which was cyclized in aq. HCl at refluxing temp. to give 3-[5-(S)-(3-aminopropyl)-2,4-dioxoimidazolidin-3-yl]benzoic acid hydrochloride, which was N-acylated with ClCO2Me and the product was coupled with Me-O2C-CH2-CH(NH2)-CO-Phg-OMe trifluoroacetate [Phg = phenylglycine residue] to give I [R = R2 = R3 = H, R1 = (CH2)3-NHCO-OMe, R4 = CO-NH-CHPh-CO2Me, Y = m-Q, Z = O, W = MeO, r = 1].

IT 157701-97-8P 157701-98-9P 157702-00-6P  
 157702-01-7P 157702-05-1P 157702-06-2P  
 157702-08-4P 157702-09-5P 157702-10-8P  
 157702-11-9P 157702-12-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as blood platelet aggregation inhibitor)  
 RN 157701-97-8 CAPLUS  
 CN Glycine, N-[N-[3-[4-[3-[(methoxycarbonyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, (S)- (9CI) (CA INDEX NAME)



RN 157701-98-9 CAPLUS  
 CN Glycine,  
 N-[N-[3-[4-(3-aminopropyl)-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, (S)- (9CI) (CA INDEX NAME)



RN 157702-00-6 CAPLUS


CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, 1-(1,1-dimethylethyl) 4-(1-methylethyl) ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 157701-99-0

CMF C32 H40 N6 O8


CDES 5:L,L



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 157702-01-7 CAPLUS

CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, 4-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488



RN 157702-05-1 CAPLUS


CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, 1-(1-methylethyl) ester, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 157702-04-0

CMF C28 H32 N6 O8


CDES 5:L,L



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 157702-06-2 CAPLUS

CN Glycine, N-[N-[3-[4-[3-[[[1-(acetyloxy)ethoxy]carbonyl]amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)




RN 157702-08-4 CAPLUS

CN Glycine, N-[N-[3-[4-[3-(acetylamino)propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)




RN 157702-09-5 CAPLUS

CN Glycine, N-[N-[3-[4-[3-(acetylamino)propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester, (S)- (9CI) (CA INDEX NAME)




RN 157702-10-8 CAPLUS

CN Glycine, N-[N-[3-[4-[[[(aminoiminomethyl)amino]methyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester, (S)- (9CI) (CA INDEX NAME)




RN 157702-11-9 CAPLUS

CN Glycine, N-[N-[3-[4-[[[imino[(methoxycarbonyl)amino]methyl]amino]methyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1-methylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 157702-12-0 CAPLUS

CN Glycine, N-[N-[3-[4-[3-(acetamidino)propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, (S)- (9CI) (CA INDEX NAME)




IT 157702-14-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as intermediate for blood platelet aggregation inhibitors)

RN 157702-14-2 CAPLUS

CN Glycine, N-[N-[3-[4-[3-[[[1,1-dimethylethoxy)carbonyl]amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-L-2-phenyl-, dimethyl ester, (S)- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 23

L15 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2000 ACS

AN 1994:271190 CAPLUS

DN 120:271190

TI Preparation of dioxoimidazolidinylacetylpeptides and related compounds as inhibitors of thrombocyte aggregation, tumor cell metastasis, and binding of osteoclasts to bone surfaces

IN Zoller, Gerhard; Just, Melitta; Jablonka, Bernd; Koenig, Wolfgang; Knolle,

Jochen

PA Cassella A.-G., Germany

SO Eur. Pat. Appl., 19 pp.


CODEN: EPXXDW

DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 566919	A1	19931027	EP 1993-105575	19930403
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	DE 4213634	A1	19931028	DE 1992-4213634	19920424
	US 5397796	A	19950314	US 1993-45994	19930412
	CA 2094773	AA	19931025	CA 1993-2094773	19930423
	JP 06116245	A2	19940426	JP 1993-98098	19930423
	IL 105511	A1	19970218	IL 1993-105511	19930423
	AU 9338203	A1	19931028	AU 1993-38203	19930428
	AU 665068	B2	19951214		
PRAI	DE 1992-4213634		19920424		
OS	MARPAT 120:271190				
GI					



I

Q1=



AB Title compds. [I; Y = (CH2)mCO, Q1; m = 1-4; R1 = (CH2)nNHX, (CH2)pC6H4NHX, :CHC6H4X1, etc.; n = 1-6; p = 1, 2; X = H, alkyl, etc; X1

=

NHX, CH2NHX, C(:NH)NH2; R2 = H, alkyl; R3 = H, Ph; R4 = CO2R5, CONMeR5, CONHR5; R5 = alkyl substituted by aryl, heterocyclyl, amino, amino acid side chain, dipeptide residue, etc.], were prepd. Thus, [(5S)-(3-guanidinopropyl)-2,4-dioxoimidazolin-3-yl]acetic acid was

coupled

with H-Asp(OtBu)-Phe-NH(CH2)4NHBOC.HCl (prepn. given) using DCC/hydroxybenzotriazole in DMF (76%) followed by deprotection with HF

and

chromatog. (90%) to give

N-[(5S)-(3-guanidinopropyl)-2,4-dioxoimidazolin-3-yl]acetic acid- 308-4488



3-yl]acetyl]aspartylphenylalanine 4-aminobutyl amide acetate. This inhibited thrombin-stimulated aggregation of human thrombocytes with IC50 = 2.0 .mu.M. Generic I drug formulations are given.

IT 154163-65-2P 154163-67-4P 154163-69-6P  
154163-70-9P 154163-71-0P 154163-72-1P  
154204-29-2P 154204-31-6P 154566-87-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as inhibitor of thrombocyte aggregation, tumor cell metastasis, and binding of osteoclasts to bone surfaces)

RN 154163-65-2 CAPLUS

CN L-Phenylalaninamide,


N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(4-aminobutyl)-, (S)-, acetate  
(9CI) (CA INDEX NAME)

CM 1

CRN 154163-64-1

CMF C26 H39 N9 O7


CDES \*



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 154163-67-4 CAPLUS

CN L-Phenylalaninamide,

N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(6-aminohexyl)-, (S)-, acetate  
(9CI) (CA INDEX NAME)


CM 1

CRN 154163-66-3  
 CMF C28 H43 N9 O7  
 CDES \*



CM 2


CRN 64-19-7  
 CMF C2 H4 O2



RN 154163-69-6 CAPLUS  
 CN L-Phenylalaninamide,  
 N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-  
 1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(4-aminobutyl)-, acetate  
 (9CI) (CA INDEX NAME)

CM 1

CRN 154163-68-5  
 CMF C30 H38 N8 O7  
 CDES 5:L,L




CM 2


Searched by John Dantzman

308-4488


CRN 64-19-7  
CMF C2 H4 O2




RN 154163-70-9 CAPLUS  
CN L-Lysinamide, N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(4-aminobutyl)- (9CI) (CA INDEX NAME)



RN 154163-71-0 CAPLUS  
CN L-Valinamide, N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(4-aminobutyl)- (9CI) (CA INDEX NAME)



RN 154163-72-1 CAPLUS  
CN Glycinamide, N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(4-aminobutyl)-L-2-phenyl- (9CI) (CA INDEX NAME)




RN 154204-29-2 CAPLUS  
Searched by John Dantzman 308-4488

CN L-Phenylalaninamide,  
N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-  
1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(6-aminohexyl)-, acetate  
(9CI) (CA INDEX NAME)


CM 1

CRN 154204-28-1  
CMF C32 H42 N8 O7  
CDES 5:L,L



CM 2


CRN 64-19-7  
CMF C2 H4 O2



RN 154204-31-6 CAPLUS  
CN L-Phenylalaninamide,  
N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-  
1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(8-aminoctyl)-, acetate  
(9CI) (CA INDEX NAME)

CM 1


CRN 154204-30-5  
CMF C34 H46 N8 O7  
CDES 5:L,L



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 154566-87-7 CAPLUS

CN L-Phenylalaninamide,

N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-(8-amino-octyl)-, (S)-, acetate


(9CI) (CA INDEX NAME)

CM 1

CRN 154566-86-6

CMF C30 H47 N9 O7

CDES \*




CM 2

CRN 64-19-7

CMF C2 H4 O2

Searched by John Dantzman

308-4488



IT 154163-76-5P 154163-78-7P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of, as intermediate for inhibitor of thrombocyte aggregation, tumor cell metastasis, and binding of osteoclasts to bone surfaces)

RN 154163-76-5 CAPLUS

CN L-Phenylalaninamide,

N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N-[4-[(1,1-dimethylethoxy)carbonyl]amino]butyl]-, 1,1-dimethylethyl ester, (S)-(9CI)


(CA INDEX NAME)



RN 154163-78-7 CAPLUS

CN L-Lysinamide, N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl-N6-[(1,1-

dimethylethoxy)carbonyl]-N-[4-[(1,1-dimethylethoxy)carbonyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






=&gt; d bib abs hitstr 24

L15 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1993:581238 CAPLUS  
 DN 119:181238  
 TI Preparation of peptide hydantoin derivatives as drugs  
 IN Koenig, Wolfgang; Zoller, Gerhard; Just, Melitta; Jablonka, Bernd  
 PA Cassella AG, Germany  
 SO Ger. Offen., 17 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4126277	A1	19930211	DE 1991-4126277	19910808
	EP 530505	A2	19930310	EP 1992-113086	19920731
	EP 530505	A3	19931229		
	EP 530505	B1	19951011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 128985	E	19951015	AT 1992-113086	19920731
	ES 2081000	T3	19960216	ES 1992-113086	19920731
	US 5389614	A	19950214	US 1992-924745	19920804
	CA 2075590	AA	19930209	CA 1992-2075590	19920807
	HU 61779	A2	19930301	HU 1992-2583	19920807
	ZA 9205934	A	19930428	ZA 1992-5934	19920807
	JP 05213895	A2	19930824	JP 1992-211801	19920807
	AU 651716	B2	19940728	AU 1992-20892	19920807
	AU 9220892	A1	19930311		
	IL 102759	A1	19970610	IL 1992-102759	19920807
PRAI	DE 1991-4126277		19910808		
OS	MARPAT 119:181238				
GI					



AB Title compds. [I; Y = (CH<sub>2</sub>)<sub>m</sub>CO, C<sub>6</sub>H<sub>4</sub>CO; m = 1-4; R<sub>1</sub> = (CH<sub>2</sub>)<sub>n</sub>NHX, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NHX, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>C(:NH)NH<sub>2</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>NHX, C<sub>6</sub>H<sub>4</sub>NHX; R<sub>1</sub>CH may also = X<sub>1</sub>C<sub>6</sub>H<sub>4</sub>CH:C; n = 3-5; X = H, alkyl, R<sub>1</sub>ONHC:NR<sub>11</sub>; X<sub>1</sub> = NHX, C(:NH)NH<sub>2</sub>; R<sub>10</sub>, R<sub>11</sub> = H, alkyl; R<sub>2</sub> = H, alkyl; R<sub>3</sub> = H, Ph; R<sub>4</sub> = H, CO<sub>2</sub>R<sub>5</sub>, CONHR<sub>5</sub>; R<sub>5</sub> = H, NHCONH<sub>2</sub>, (substituted) alkyl], were prepd. as inhibitors of thrombocyte aggregation, metastasis, and of osteoclast binding to bone surfaces (no data). Thus, [5(R,S)-(4-formamidobenzyl)-2,4-dioxoimidazolidin-3-yl]acetylaspartylvaline was prepd. in 5 steps starting with 4-formamidino-DL-phenylalanine dihydrochloride.

IT 150376-14-0P 150376-18-4P 150376-22-0P

Searched by John Dantzman 308-4488



150376-23-1P 150376-24-2P 150376-25-3P

150376-28-6P 150376-29-7P 150376-33-3P

150376-34-4P 150376-38-8P 150376-39-9P

150376-42-4P 150376-43-5P 150376-46-8P


150376-47-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as drug intermediate)

RN 150376-14-0 CAPLUS

CN L-Valine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150376-18-4 CAPLUS


CN L-Valine,

N-[N-[[4-[3-[(aminoiminomethyl)amino]propyl]-3-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 150376-22-0 CAPLUS


CN L-Valine, N-[N-[[4-[[(1,1-dimethylethoxy)carbonyl]amino]butyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 150376-23-1 CAPLUS


CN .beta.-Alanine, N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 150376-24-2 CAPLUS

CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 150376-25-3 CAPLUS


CN .beta.-Alanine, N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 150376-28-6 CAPLUS  
 CN L-Valine, N-[N-[[4-[(4-aminophenyl)methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 150376-29-7 CAPLUS  
 CN L-Valine, N-[N-[[4-[(4-nitrophenyl)methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)




RN 150376-33-3 CAPLUS  
 CN L-Valine, N-[N-[[4-[[[imino(nitroamino)methyl]amino]phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 150376-34-4 CAPLUS

CN L-Valine,

N-[N-[[4-[[4-[[imino(nitroamino)methyl]amino]phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA


INDEX  
NAME)

RN 150376-38-8 CAPLUS

CN L-Valine, N-[N-[[4-[(4-cyanophenyl)methylene]-3-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 150376-39-9 CAPLUS


CN L-Valine, N-[N-[[4-[(4-cyanophenyl)methylene]-3-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488

Double bond geometry unknown.




RN 150376-42-4 CAPLUS

CN L-Valine, N-[N-[[4-[(4-cyanophenyl)methylene]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 150376-43-5 CAPLUS

CN L-Valine, N-[N-[[4-[(4-cyanophenyl)methylene]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 150376-46-8 CAPLUS


CN L-Valine,  
N-[N-[3-[4-[3-[[imino(nitroamino)methyl]amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-, bis(1,1-dimethylethyl) ester, (S)- (9CI) (CA INDEX NAME)



RN 150376-47-9 CAPLUS

CN L-Valine,

N-[N-[3-[4-[3-[[imino(nitroamino)methyl]amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



IT 150376-03-7P 150376-04-8P 150376-05-9P

150376-06-0P 150376-07-1P 150376-08-2P

150376-09-3P 150376-10-6P 150376-11-7P

150391-41-6P 150391-42-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as inhibitor of thrombocyte aggregation, metastasis, and osteoclast binding to bone surfaces)

RN 150376-03-7 CAPLUS


CN L-Valine, N-[N-[4-[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150376-04-8 CAPLUS


CN L-Valine, N-[N-[[4-(4-aminobutyl)-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



RN 150376-05-9 CAPLUS


CN .beta.-Alanine, N-[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 150376-06-0 CAPLUS

CN Glycine, N-[N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-L-2-phenyl- (9CI) (CA INDEX NAME)




RN 150376-07-1 CAPLUS

CN .beta.-Alanine, N-[[4-[[4-(aminoiminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 150376-08-2 CAPLUS

CN L-Valine, N-[N-[[4-[[4-(4-aminophenyl)methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



RN 150376-09-3 CAPLUS


CN L-Valine, N-[N-[[4-[[4-(aminoiminomethyl)amino]phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



RN 150376-10-6 CAPLUS


CN L-Valine, N-[N-[[4-[[4-(aminomethyl)phenyl]methyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)





RN 150376-11-7 CAPLUS


CN L-Valine, N-[N-[3-[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]benzoyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



RN 150391-41-6 CAPLUS


CN L-Valine,

N-[N-[4-[3-[(aminoiminomethyl)amino]propyl]-3-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl]-, (S)- (9CI) (CA INDEX NAME)



RN 150391-42-7 CAPLUS


CN L-Valine, N-[4-[4-(aminomethyl)phenyl]methyl]-3-methyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 25

L15 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1992:106788 CAPLUS  
 DN 116:106788  
 TI Preparation of (2,4-dioxoimidazolidin-3-yl)acetylaspartic acid amides as  
 thrombocyte aggregation inhibitors  
 IN Koenig, Wolfgang; Just, Melitta; Jablonka, Bernd  
 PA Hoechst A.-G., Germany  
 SO Ger. Offen., 9 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4009506	A1	19910926	DE 1990-4009506	19900324
	EP 449079	A2	19911002	EP 1991-104195	19910319
	EP 449079	A3	19920826		
	EP 449079	B1	19951115		
	R: BE, DE, DK, ES, FR, GB, GR, IT, LU, NL				
	ES 2082026	T3	19960316	ES 1991-104195	19910319
	NO 9101158	A	19910925	NO 1991-1158	19910322
	CA 2038848	AA	19910925	CA 1991-2038848	19910322
	AU 9173653	A1	19911003	AU 1991-73653	19910322
	AU 634039	B2	19930211		
	BR 9101121	A	19911105	BR 1991-1121	19910322
	ZA 9102178	A	19911224	ZA 1991-2178	19910322
	JP 04217962	A2	19920807	JP 1991-81158	19910322
	IL 97657	A1	19950831	IL 1991-97657	19910322
	US 5686421	A	19971111	US 1995-467526	19950606
PRAI	DE 1990-4009506		19900324		
	US 1991-673512		19910322		
OS	MARPAT 116:106788				
GI					



AB Title compds. [I; n = 3,4; R1 = alkyl, R3NH(R4N:)C; R3,R4 = H, alkyl; R2 =  
 H, NHCONH2, (substituted) alkyl, amino, amino acid residue, OH, SH,  
 etc.],  
 were prepd. as thrombocyte aggregation inhibitors (no data). Thus,  
 [5-(3-guanidinopropyl)-2,4-dioxoimidazolidin-3-yl]acetyl-L-aspartic acid  
 4,4'-dimethoxybenzhydrylamide was prepd. by soln. phase methods starting  
 from Z-Asp(OCMe3)-OH.

Searched by John Dantzman

308-4488


IT 139113-85-2P 139113-86-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as thrombocyte aggregation inhibitor)


RN 139113-85-2 CAPLUS

CN Butanoic acid, 3-[[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-[[bis(4-methoxyphenyl)methyl]amino]-4-oxo-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 139113-86-3 CAPLUS

CN Butanoic acid, 4-amino-3-[[[4-[3-[(aminoiminomethyl)amino]propyl]-2,5-dioxo-1-imidazolidinyl]acetyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 26

L15 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2000 ACS  
AN 1985:615779 CAPLUS  
DN 103:215779  
TI Cleavage of Z-group and formation of hydantoin during alkaline  
saponification of Z-peptide esters  
AU Schwenzer, B.; Weber, E.; Losse, G.  
CS Sekt. Chem., Tech. Univ. Dresden, Dresden, DDR-8027, Ger. Dem. Rep.  
SO J. Prakt. Chem. (1985), 327(3), 479-86  
CODEN: JPCEAO; ISSN: 0021-8383  
DT Journal  
LA German  
OS CASREACT 103:215779  
GI





AB During the sapon. of Z-Arg(NO<sub>2</sub>)-Gly-Phe-Phe-OR (I; Z = PhCH<sub>2</sub>O<sub>2</sub>C, R = Me)  
(II) by aq. NaOH, the Z group was cleaved and substantial amts. of  
hydantoin III was formed as a byproduct. III was identified by <sup>13</sup>C NMR  
spectroscopy. This undesired side reaction was suppressed by the addn.  
of  
benzyl alc. Thus, the sapon. of II for 1 h in the presence of 50 equivs.  
of benzyl alc. gave 48% acid I (R = H) without formation of III.  
IT **99260-32-9P**  
RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, during sapon. of benzyloxycarbonyl tetrapeptide Me  
ester)  
RN 99260-32-9 CAPLUS  
CN L-Phenylalanine, N-[N-[[4-[3-[[imino(nitroamino)methyl]amino]propyl]-2,5-  
dioxo-1-imidazolidinyl]acetyl]-L-phenylalanyl]-, (S)- (9CI) (CA INDEX  
NAME)



=&gt; d bib abs hitstr 27

L15 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1984:112180 CAPLUS  
 DN 100:112180  
 TI Silver halide color photographic light-sensitive materials  
 IN Sesaki, Noboru; Sakanoue, Kei; Ichijima, Seiji; Kobayashi, Hidetoshi;  
 Adachi, Keiichi  
 PA Fuji Photo Film Co., Ltd. , Japan  
 SO Eur. Pat. Appl., 133 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 96873	A2	19831228	EP 1983-105722	19830610
	EP 96873	A3	19840307		
	EP 96873	B1	19871202		
	R: DE, FR, GB				
	JP 58217932	A2	19831219	JP 1982-101226	19820611
	JP 63044218	B4	19880902		
	CA 1248803	A1	19890117	CA 1983-430151	19830610
	US 4975359	A	19901204	US 1989-349457	19890509
PRAI	JP 1982-101226		19820611		
	US 1983-503440		19830613		
	US 1984-679740		19841210		
	US 1987-42557		19870424		
GI					






AB Photog. material providing images of high granularity and sharpness contains a combination of a nondiffusing coupler and a DIR compd. releasing a diffusing development inhibitor or its precursor through a coupling reaction. These compds. can be situated in the same layer or a plurality of layers which are sensitive to the same color. Thus, a multilayer color photog. material was prep'd. contg. a cellulose triacetate support, an antihalation layer, a gelatin interlayer, a first red-sensitive Ag(Br,I) emulsion (5 mol % AgI) contg. coupler I 0.01, DIR compd. 0.0006 mol/mol Ag, a second red-sensitive Ag(Br,I) emulsion (7 mol % AgI), an intermediate layer, first and second green-sensitive emulsion layers, a yellow filter layer, and first and second blue-sensitive emulsion layers. The element was exposed, processed in a developer contg. 4-(N-ethyl-N-.beta.-hydroxyethylamino)-2-methylaniline sulfate, bleached, fixed, and stabilized to give a cyan image with RMS granularity (D = fog + 0.3) of 0.015 and a MTF value of GL at frequency 10/mm of 1.05.


IT **88935-39-1**  
 RL: USES (Uses)  
 (photog. color multilayer material providing images of high granularity and sharpness contg. nondiffusing color coupler and)

RN 88935-39-1 CAPLUS  
 CN Carbamothioic acid,  
 [[1-[1-[[[5-[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-chlorophenyl]amino]carbonyl]-3,3-dimethyl-2-oxobutyl]-3-methyl-2,5-dioxo-4-imidazolidinyl]methyl]propyl-,  
 S-(1-phenyl-1H-tetrazol-5-yl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




=> d bib abs hitstr 28


L15 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2000 ACS  
 AN 1978:597923 CAPLUS  
 DN 89:197923  
 TI N-Terminal cyclization of peptides with N,N'-carbonyldiimidazole or  
 N,N'-thiocarbonyldiimidazole  
 AU Esser, Franz; Roos, Otto  
 CS C. H. Boehringer Sohn Abt. Pharmachem., Ingelheim, Ger.  
 SO Angew. Chem. (1978), 90(6), 495-6  
 CODEN: ANCEAD; ISSN: 0044-8249  
 DT Journal  
 LA German  
 GI



III



IV



V


AB Peptides  $\text{H}_2\text{NCHRCONHCHR}_1\text{COR}_2$  (I; R = L- $\text{CH}_2\text{CO}_2\text{CH}_2\text{Ph}$ , H, D- and L-3-indolylmethyl;  $\text{R}_1$  = L- $\text{CH}_2\text{Ph}$ , L-3-indolylmethyl, L- $\text{CH}_2\text{CHMe}_2$ ;  $\text{R}_2$  =  $\text{NH}_2$ , Met-Gly- $\text{NH}_2$ , Asp-Phe- $\text{NH}_2$ ) were cyclized by N,N'-carbonyldiimidazole (II) to give the corresponding hydantoins III, whereas I (R = L-3-indolylmethyl,  $\text{R}_1$  = L- $\text{CH}_2\text{CHMe}_2$ ,  $\text{R}_2$  = Asp-Phe- $\text{NH}_2$ ) was cyclized by N,N'-thiocarbonyldiimidazole to give thiohydantoin IV.  
 H-.beta.-Ala-Phe- $\text{NH}_2$  was cyclized by II to give pyrimidinedione V.  
 IT **66610-80-8P 66674-35-9P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, by cyclization of N-terminal peptides with carbonyldiimidazole)

Searched by John Dantzman

308-4488

RN 66610-80-8 CAPLUS

CN L-Phenylalaninamide, N-[2-[4-(1H-indol-3-ylmethyl)-2,5-dioxo-1-imidazolidinyl]-4-methyl-1-oxopentyl]-L-.alpha.-aspartyl-, [S-(R\*,S\*)]-(9CI) (CA INDEX NAME)



RN 66674-35-9 CAPLUS

CN L-Phenylalaninamide, N-[2-[4-(1H-indol-3-ylmethyl)-2,5-dioxo-1-imidazolidinyl]-4-methyl-1-oxopentyl]-L-.alpha.-aspartyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)

